Illumina Ventures has led a series A round for SerImmune, which will use the funding to enhance its immune system mapping platform.
SerImmune, a US-based developer of mapping technology for the immune system, has raised $8m in a series A round, led by Illumina Ventures, an independently-managed venture capital fund backed by genomics company Illumina.
US-based pharmaceutical company Merck & Co also contributed to the round, through an unnamed subsidiary, and was joined by undisclosed additional investors.
SerImmune has built a system that can map the human immune system to help with the development of therapeutic or diagnostic products. It will…
